Northern Trust’s Provention Bio, Inc. Common Stock PRVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-641,249
| Closed | -$15.5M | – | 4656 |
|
|
2023
Q1 | $15.5M | Buy |
641,249
+18,895
| +3% | +$237K | ﹤0.01% | 1724 |
|
|
2022
Q4 | $6.58M | Buy |
622,354
+57,292
| +10% | +$462K | ﹤0.01% | 2301 |
|
|
2022
Q3 | $2.54M | Buy |
565,062
+47,930
| +9% | +$218K | ﹤0.01% | 2887 |
|
|
2022
Q2 | $2.07M | Sell |
517,132
-4,415
| -0.8% | -$20.9K | ﹤0.01% | 3043 |
|
|
2022
Q1 | $3.82M | Sell |
521,547
-18,276
| -3% | -$109K | ﹤0.01% | 2742 |
|
|
2021
Q4 | $3.03M | Sell |
539,823
-26,382
| -5% | -$168K | ﹤0.01% | 3003 |
|
|
2021
Q3 | $3.62M | Sell |
566,205
-6,398
| -1% | -$41.1K | ﹤0.01% | 2938 |
|
|
2021
Q2 | $4.83M | Sell |
572,603
-24,978
| -4% | -$202K | ﹤0.01% | 2862 |
|
|
2021
Q1 | $6.27M | Buy |
597,581
+19,555
| +3% | +$275K | ﹤0.01% | 2607 |
|
|
2020
Q4 | $9.79M | Sell |
578,026
-12,391
| -2% | -$186K | ﹤0.01% | 2259 |
|
|
2020
Q3 | $7.58M | Buy |
590,417
+380,366
| +181% | +$4.8M | ﹤0.01% | 2269 |
|
|
2020
Q2 | $2.96M | Buy |
210,051
+138,823
| +195% | +$1.75M | ﹤0.01% | 2821 |
|
|
2020
Q1 | $655K | Buy |
71,228
+4,099
| +6% | +$52.8K | ﹤0.01% | 3377 |
|
|
2019
Q4 | $1M | Buy |
67,129
+16,870
| +34% | +$150K | ﹤0.01% | 3398 |
|
|
2019
Q3 | $343K | Buy |
50,259
+19,811
| +65% | +$200K | ﹤0.01% | 3629 |
|
|
2019
Q2 | $368K | Buy |
+30,448
| New | +$166K | ﹤0.01% | 3641 |
|
Other funds holding PRVB
Northern Trust's PRVB Position: Q2 2023 in Review
Northern Trust sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 641,249 shares — an estimated $15.5M sold.
Northern Trust first reported a position in PRVB in Q2 2019 and held it in 16 quarters. The position peaked at $15.5M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.
- Northern Trust reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Northern Trust sold 641,249 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $15.5M.
- Northern Trust first reported a position in Provention Bio, Inc. Common Stock in Q2 2019 and held it in 16 quarters.
- Northern Trust's Provention Bio, Inc. Common Stock position peaked at $15.5M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.
Based on Northern Trust's 13F filing for Q2 2023, filed 11 Aug 2023.